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Objective: To explore the relationship between the external validity and the internal validity of hyper-
tension RCTs conducted in China.
Methods: Comprehensive literature searches were performed in Medline, Embase, Cochrane Central
Register of Controlled Trials (CCTR), CBMdisc (Chinese biomedical literature database), CNKI (China
National Knowledge Infrastructure/China Academic Journals Full-text Database) and VIP (Chinese sci-
entiﬁc journals database) as well as advanced search strategies were used to locate hypertension RCTs.
The risk of bias in RCTs was assessed by a modiﬁed scale, Jadad scale respectively, and then studies with 3
or more grading scores were included for the purpose of evaluating of external validity. A data extract
form including 4 domains and 25 items was used to explore relationship of the external validity and the
internal validity. Statistic analyses were performed by using SPSS software, version 21.0 (SPSS, Chicago,
IL).
Results: 226 hypertension RCTs were included for ﬁnal analysis. RCTs conducted in university afﬁliated
hospitals (P < 0.001) or secondary/tertiary hospitals (P < 0.001) were scored at higher internal validity.
Multi-center studies (median ¼ 4.0, IQR ¼ 2.0) were scored higher internal validity score than single-
center studies (median ¼ 3.0, IQR ¼ 1.0) (P < 0.001). Funding-supported trials had better methodolog-
ical quality (P < 0.001). In addition, the reporting of inclusion criteria also leads to better internal validity
(P ¼ 0.004). Multivariate regression indicated sample size, industry-funding, quality of life (QOL) taken as
measure and the university afﬁliated hospital as trial setting had statistical signiﬁcance (P < 0.001,
P < 0.001, P ¼ 0.001, P ¼ 0.006 respectively).
Conclusion: Several components relate to the external validity of RCTs do associate with the internal
validity, that do not stand in an easy relationship to each other. Regarding the poor reporting, other
possible links between two variables need to trace in the future methodological researches.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
As the design and conduct has effectively eliminated the pos-
sibility of bias and confounding [1], randomized controlled trials
(RCTs) having a favorable internal validity and being the gold
standard for determining the effects of treatments, have been
widely recognized in clinical researches [2e5]. Much of the meth-
odological discussion around RCTs is framed in terms of the notions
of internal and external validity. Both validities appeal to us all as
obvious requisites for the worth of a RCT. Internal validity reﬂectsInc. This is an open access article uthe extent of conﬁdence to RCTs' results, while the external validity
needs to be emphasized too as it reﬂects the extent of RCT's con-
clusions to be generalized [6,7]. If a RCT is not externally valid, then
its results cannot be said to hold outside of the research setting, and
thus, even if internally valid, we cannot use its results to say any-
thing relevant of the clinical setting; if RCTs were misused or the
results from RCTs were irrelevant to the patients in a particular
clinical setting [1,8,9], that may adversely affect to patients. Lack of
external validity is frequently advocated as one of the obstacles to
the translation of research evidence into clinical practice, which is
why interventions found to be effective in clinical trials and rec-
ommended in guidelines are underused in clinical practice [1,10,11].
Although most of the current arguments and disputes around thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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surprising that not much has been researched systematically about
the relationship between the internal and the external validity of
RCTs. Hypertension has become a serious burden disease in China
[12,13]; although a great number of clinical trials on hypertension
have been conducted within China, few studies were successful in
developing as evidence based information and disseminating to
patients under speciﬁc circumstances [13]. Taking the example of
hypertension, this study intends to explore the relationship be-
tween the external and internal validity of RCTs systematically.
2. Materials and methods
2.1. Search strategy and study selection
A systematic literature search was conducted to identify all
relevant randomized controlled trials on hypertension using data-
bases (incept-2010.6) including Medline (Ovid), Embase, CCTR
(Cochrane Central Register of Controlled Trials, Ovid), CBMdisc
(Chinese biomedical literature database), CNKI (China National
Knowledge Infrastructure/China Academic Journals Full-text Data-
base) and VIP (Chinese scientiﬁc journals database); articles with
‘hypertension’, ‘randomized controlled trial’, ‘controlled clinical
trial’ and ‘random allocation’ as general keyword terms, free words
or exploded MeSH terms were searched as English and corre-
sponding Chinese search terms to identify studies from above da-
tabases. In addition, reference lists of included articles were
screened for additional articles.
Titles and abstracts of all citations were independently evalu-
ated by two reviewers (WYX and KD). The full texts of the poten-
tially relevant articles were obtained and independently evaluated
by the same two authors. Disagreement was resolved by consensus.
Studies were included if (1) drug therapy for primary hypertension,
covering the six kinds of anti-hypertension drugs in which rec-
ommended by WHO were included (ACEI, Angiotensin-Converting
Enzyme Inhibitor; ARB, Angiotensin Receptor Blocker; CCB, Calcium
Channel Blocker; alpha-blocker; beta-blocker; Diuretics); (2)
studies grading score equal or greater than 3. Studies were
excluded if (1) recruited patients with secondary hypertension; (2)
that published as abstracts only; (3) reported partial data from
multi-center research.
2.2. Internal validity assessment
The scale for assessing internal validity of RCTs were modiﬁed
from two RCTs-based tools, the Jadad scale [13] and the evaluation
criteria of risk of bias in Cochrane Review's Handbook [14]. The
scale developing for RCTs include ﬁve items: randomization (0e2
points), allocation concealment (0e2 points), blinding (0e2
points), attrition (0e2 points) and baseline condition (0e1 points);
the maximum score for a perfect RCT is 9. To study the relationship
between internal validity and external validity, all included RCTs
were divided into four groups (3-score group, 4-score group, 5-
score group and 6e9 scores group).
Meanwhile, 50 RCTs were selected randomly using a computer-
generated list to validate inter-rater agreement of applying the
modiﬁed scale. The agreement for each item and the whole scale
was explained by percentage of actual agreement as well as Kappa
coefﬁcient. We adopted the Kappa values of <0 rates as less than
chance agreement, 0.01e0.20 as slight agreement, 0.21e0.40 as fair
agreement, 0.41e0.60 as moderate agreement, 0.61e0.80 as sub-
stantial agreement, and 0.81e0.99 as almost perfect agreement
[15]. In addition, Jadad scale [16] was taken as reference standard to
validate criterion validity of this modiﬁed scale. Two authors (ZX,
WYX) conducted a critical appraisal of the internal validity of allstudies by using the modiﬁed scale; any disagreement between
reviewers was submitted to the third author (KD) and resolved by
consensus.
2.3. Data abstraction for evaluating external validity
From each publication, information was extracted regarding
characteristics of included RCTs, such as subjects recruitment,
baseline characteristics of subjects, interventions, outcomes and
any further information about external validity by a pre-developed
form [17,18]. The data extract form for evaluating external validity
includes 4 domains and 25 items totally, the checklist has been
developed by listing the most commonly used assessment criteria
for clinical studies [1,35]. Of this, the domain of “source” has 5
items: region of trial setting, research setting, research date,
number of centers involved, funding source; domain of “subjects
recruitment” includes 7 items: location, setting, method, duration
of recruitment, number of eligible patients, number of patients not
meeting inclusion criteria, number of patients who refusing
participation; domain of “baseline characteristics of subjects” has 8
items: sample size, source of patients, age, gender, diagnosis
criteria, duration of disease, state of disease, complications; the last
4 domain relates to patient reported outcomes, includes “effec-
tiveness outcomes” and “adverse events” respectively. A meeting
followed in which the ratings were reviewed and any disagree-
ments were resolved by discussion and consensus with the third
author (KD). Two reviewer (ZX, WY) independently completed all
the data extractions.
2.4. Statistical analysis
A description of the data included rate and proportion used for
dichotomous data, and medians (inter-quartile range, IQR) or
mean ± SD (standard deviation) for continuous data. Possible dif-
ferences between groups were calculatedwithManneWhitney test
or KruskaleWallis test for continuous variables. Correlation co-
efﬁcients were taken to validate criterion validity of the modiﬁed
scale for internal validity. The statistical signiﬁcance level was set at
0.05 and all tests were two-sided. Bonferroni correctionwas used of
multiple comparisons if possible; in that case, the statistical sig-
niﬁcance level was re-settled accordingly. Multiple linear re-
gressions were used to test the relationship of internal and external
validity in terms of characteristics of RCTs, baseline characteristics
of subjects, interventions and outcomes, the grading score of in-
ternal validity was taken as dependent variable. Data analysis was
done using SPSS software, version 21.0 (SPSS, Chicago, IL).
3. Results
3.1. Flow of included studies
1197 RCTs were identiﬁed from the searches (excluding 136
duplicates and 4888 non-relevant articles), additional 99 RCTs were
excluded based on the inclusion criteria; after that, the evaluation
of internal validity was performed by applying the modiﬁed scale,
226 RCTs with internal validity scores of 3 remained for ﬁnal
analysis (Fig. 1).
3.2. Validation of the modiﬁed scale for grading internal validity
In order to evaluate the criterion validity of the scale, we select
50 RCTs randomly using a computer-generated list to validate inter-
rater agreement. Total mean score was converted into the per-
centage of the maximum score for the modiﬁed scale, the ICC
against Jadad score was 0.84, that is, the results of the modiﬁed
Fig. 1. Flow of the RCTs selection.
Table 2
Grading scores of internal validity for included RCTs.
Grading score n Percentage (%) Cumulative percentage (%)
9 1 0.4 0.4
8 2 0.9 1.3
7 4 1.8 3.1
6 17 7.5 10.6
5 27 11.9 22.6
4 48 21.2 43.8
3 127 56.2 100.0
RCT, Randomized Controlled Trial.
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And then, the rater-agreement validation of full-sample RCTs
was performed. Substantial agreements were also observed for all
of the items. Specially, the rater agreements for each items varied
from 88% to 100% with a total percentage of 76%, of that, 4 items
reach to almost perfect agreements (>90.0%); however, the kappa
values of inter-rater ranged widely from 0.63 to 0.90 with a total of
0.72, of that, 3 items had excellent agreements (above 80.0%) be-
tween raters (Table 1).
3.3. Internal validity assessment by applying the modiﬁed scale
226 RCTs with a score of 3 or more were included after applying
the modiﬁed scale. The median grade of included RCTs was 3 with
IQR of 1, the minimumwas 3, and maximumwas 9. Of those, 56.2%
(n ¼ 127) of RCTs were scored at 3, only 3.1% (n ¼ 7) of RCTs were
7 (Table 2).
3.4. The relationship between the internal validity and external
validity
3.4.1. Characteristics of RCTs
3.4.1.1. Research setting and research date. The median scores of
internal validity within RCTs conducted in two regions (south China
or north China) were both at 3.0 with an IQR of 1.0 (P ¼ 0.200). The
scores among RCTs conducted in different level hospitals were
calculated and signiﬁcant difference was found (P < 0.001), withTable 1
Assessment of the internal validity of selected 226 RCTs and agreements of inter-raters.
Item Yes, n (%) No, n (%)
Randomization 48 (21.2) 3 (1.3)
Allocation concealment 14 (6.2) 212 (93.8)
Blinding 82 (36.3) 73 (32.3)
Attrition 16 (7.1) 98 (43.4)
Baseline condition 185 (81.9) 41 (18.1)
Total e eaverages of 3.00 (IQR ¼ 0.00) and 4.00(IQR ¼ 2.00) respectively;
73.5% RCTs were conducted in university afﬁliated hospitals and
were scored at higher points too (P < 0.001) (Table 3). Based on the
RCTs carried out in the periods before 2000, 2001 to 2005 and 2006
to 2009 respectively, the difference of internal validity was not
statistically signiﬁcant (P ¼ 0.272) (Table 3).
3.4.1.2. Number of research centers and funding status.
Multi-center studies were graded higher score of internal validity
than that of single-center studies with medians of 4.0 and 3.0
respectively (P < 0.001) (Table 3). In addition, RCTs with funding
support also have higher score of internal validity (P < 0.001). We
found that industry (manufacturer of the experimental drug) ac-
counts 30.8% of funding source in China. RCTs either drug industry-
funded or/and nonproﬁt-funded (e.g., from the government or no-
proﬁt institutes) had higher score of internal validity than that of
RCTs without funding, the median scores were 4.0 (IQR ¼ 2.0), 4.0
(IQR ¼ 1.0) and 6.0 (IQR ¼ 2.0) accordingly (Table 3).
3.4.2. Baseline characteristics of subjects
3.4.2.1. Gender and age. 200 (88.5%) RCTs reported the proportion
of female patients, no signiﬁcant difference was observed
(P ¼ 0.582) among RCTs with different grades of internal validity
(Table 4). Similar result for age was observed too, patient ages were
presented in 83.6% (n ¼ 189) of RCTs and no statistical signiﬁcance
was found (P ¼ 0.568) (Table 4).
3.4.2.2. Sample source and sample size. RCTs recruited patients in
the out-patient department was more likely to have a higher in-
ternal validity, that is, the patients source was relevant to internal
validity (P ¼ 0.043) (Table 3).
Sample size within group 4 (median ¼ 221, IQR ¼ 235) was
signiﬁcantly larger than that of two groups (group 1, median ¼ 94,
IQR ¼ 75, P < 0.001; group 2, median ¼ 99.5, IQR ¼ 115.5,
P ¼ 0.006). Sample sizes within groups 1, 2 and 3 did not differ
signiﬁcantly from each other (P > 0.0125).
3.4.2.3. Inclusion/exclusion criteria and diagnostic criteria.
Internal validity in RCTs with setting inclusion criteria was higher
signiﬁcantly than that of without (P ¼ 0.004); however, noUnclear, n (%) Raters P value
Agreements Kappa
175 (77.4) 98% 0.90 0.001
0 (0.0) 100% e e
71 (31.4) 96% 0.88 0.001
112 (49.6) 88% 0.63 0.001
e 90% 0.80 0.001
e 76% 0.72 0.001
Table 3
Scores of methodological quality of included RCTs according to different strata.
n (%) Grading internal validity [median (IQR)] P value
External characteristics of RCTs
Research setting
Region of trial setting, south China vs north China 105(53.3%)/92(46.7%) 3.0(1.0)/3.0(1.0) 0.200
University afﬁliated hospital, yes/no 166(73.5%)/60(16.5%) 4.00(2.00)/3.00(0.00) <0.001
Hospital class primary vs secondary or tertiary 41(18.1%)/185(81.9%) 3.00(0.00)/4.00(2.00) <0.001
Date of study 2000/2005/2006 vs 2009 45(19.9%)/92(40.7%)/89(39.4%) 3.00(1.00)/4.00(1.75)/3.00(1.00) 0.272
Number of centers involved, single-center vs multi-center study 172(76.1%)/54(23.9%) 3.0(1.0)/4.0(2.0) <0.001
Funding sourcea
Funding,yes/no 82(36.3%)/144(63.7%) 4.0(2.0)/3.0(1.0) <0.001
Industry,yes/no 64(30.8%)/144(69.2%) 4.0(2.0)/3.0(1.0) <0.001
Non-proﬁt,yes/no 11(7.1%)/144(92.9%) 4.0(1.0)/3.0(1.0) 0.015
mixed,yes/no 7(4.6%)/144(95.4) 6.0(2.0)/3.0(1.0) 0.001
Baseline characteristics of subjects
Source of patients, outpatient/inpatient/both 82(73.9%)/7(6.3%)/22(19.8%) 3.00(2.00)/3.00(0.00)/3.00(0.00) 0.043
Inclusion and exclusion criteria
Inclusion criteria, yes/no 199(88.4%)/26(11.6%) 3.00(1.00)/3.00(0.00) 0.004
Exclusion criteria, yes/no 190(88.4%)/25(11.6%) 3.00(1.00)/7.00(6.00) 0.480
Diagnostic criteria
Diagnostic criteria, yes/no 125(55.6%)/100(44.4%) 3.00(1.00)/3.00(1.00) 0.731
Diagnosis criteria, WHO/China 84(70.0%)/36(30.0%) 3.00(1.00)/3.00(2.00) 0.802
Complications
Complications excluded, yes/no 185(81.9%)/41(18.1%) 3.00(1.00)/3.00(1.50) 0.633
CHD excluded, yes/no 131(58.0%)/95(42.0%) 3.00(1.00)/3.00(1.00) 0.066
Stroke excluded, yes/no 104(46.0%)/122(54.0%) 3.50(2.00)/3.00(1.00) 0.081
Renal insufﬁciency excluded, yes/no 167(73.9%)/59(26.1%) 3.00(1.00)/3.00(2.00) 0.865
Diabetes excluded, yes/no 92(40.7%)/134(59.3%) 3.00(1.00)/3.00(1.00) 0.445
Heart failure excluded, yes/no 128(56.6%)/98(43.4%) 3.00(2.00)/3.00(1.00) 0.060
Interventions
Drugs
alpha-blocker 25 (11.1%) 3.00 (1.00) 0.196
beta-blocker 19 (8.4%) 4.00 (1.00)
ACEI 29 (12.8%) 3.00 (1.00)
ARB 59 (26.1%) 3.00 (2.00)
CCB 43 (19.0%) 4.00 (2.00)
Diuretics 8 (3.5%) 4.00 (1.75)
Drug combination or compound preparation 43 (19.0%) 3.00 (1.00)
Outcomes
Effectiveness outcomes
Blood pressure value, yes/no 213(94.2%)/13(5.8%) 3.00(1.00)/3.00(4.00) 0.880
Effective rate, yes/no 175(77.4%)/51(22.6%) 3.00(2.00)/3.00(1.00) 0.058
Laboratory index, yes/no 55(24.3%)/171(75.7%) 3.00(1.00)/3.00(2.00) 0.078
Quality of life, yes/no 14(6.2%)/212(93.8%) 4.50(4.00)/3.00(1.00) 0.025
IQR, inter-quartile range.
a Industry, manufacturer of the experimental drug; nonproﬁt, such as the government; mixed, both industry and nonproﬁt sources.
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criteria or not (P ¼ 0.480) or in total number of exclusion criteria
(P ¼ 0.109) (Table 4).
Regard to diagnostic criteria, internal validity showed no sig-
niﬁcant difference in reporting diagnostic criteria or not
(P¼ 0.731); in addition, diagnostic criteria sourcewas not related to
internal validity (P ¼ 0.802) (Table 3).
3.4.2.4. Duration and state of disease. Duration of disease in four
groups did not differ signiﬁcantly from each other (P ¼ 0.278)
(Table 4). Proportion of grade III hypertension was only reported in
4 RCTs, of those, 3 RCTs (proportion range: 0.163e0.317) scored 3
and 1 RCT with reporting of proportion of 0.068 was scored at 1.
3.4.2.5. Complications. 185 RCTs (81.9%) excluded patients with
complications showed no signiﬁcant difference in grading internal
validity (P ¼ 0.633) (Table 3). Of those, 58.0% patients had coronary
heart disease (P ¼ 0.066), 25% patients suffered from stroke
(P ¼ 0.081),46.0% patients with renal insufﬁciency (P ¼ 0.865),
40.7% patients with diabetes (P ¼ 0.445) and 56.6% patients with
heart failure (P ¼ 0.060) removed, that is, signiﬁcant differences of
internal validity were not observed among RCTs excluding com-
plications or not (P > 0.05) (Table 3).3.4.3. Drugs and course of treatment
Regard to addressed drugs, 19.0% (n ¼ 43) RCTs were designated
to test drug combination or compound preparation, while the
proportion of RCTs designated to test single drug was 81.0%
(n ¼ 183). Categories of drug therapy showed no signiﬁcant dif-
ference in internal validity (P¼ 0.196). Course of treatment was not
relevant to internal validity (P ¼ 0.070) (Table 4).3.4.4. Outcomes
3.4.4.1. Safety measure. RCTs having a higher internal validity were
more likely to report lower adverse events rate (P ¼ 0.047)
(Table 4). of those, adverse events rate for group 4 (median ¼ 0.10;
IQR ¼ 0.11) (Table 3) was signiﬁcantly lower than that in group 2
(median ¼ 0.15; IQR ¼ 0.16, P ¼ 0.011). Adverse events rate in
groups 1,2 and 3 did not differ signiﬁcantly from one another
(P > 0.0125) (Table 3).3.4.4.2. Efﬁcacy measure. Internal validity within RCTs using blood
pressure value (P ¼ 0.880), response rate (P ¼ 0.058), or laboratory
index (P ¼ 0.078) as outcomes or not were different insigniﬁcantly;
however, signiﬁcant difference was observed in adopting quality of
life as the outcome or not (P ¼ 0.025) (Table 3).
Table 4
Characteristics of included RCTs according to different groups of internal validity
score.
Grading internal validity n (%) Median (IQR) Mean rank P value
Baseline characteristics of subjects
Proportion of female patients
Group 1 111 (55.5%) 0.41 (0.11) 96.03 0.582
Group 2 43 (21.5%) 0.44 (0.09) 107.85
Group 3 23 (11.5%) 0.42 (0.10) 99.13
Group 4 23 (11.5%) 0.44 (0.16) 109.72
Age
Group 1 100 (52.9%) 53.00 (8.71) 98.79 0.568
Group 2 43 (22.8%) 53.50 (4.85) 96.19
Group 3 24 (12.7%) 51.68 (4.57) 82.35
Group 4 22 (11.6%) 52.21 (9.34) 89.27
Number of exclusion criteria
Group 1 120 (56.1%) 6.00 (4.00) 99.33 0.109
Group 2 47 (22.0%) 7.00 (6.00) 117.06
Group 3 23 (10.7%) 6.00 (7.00) 108.59
Group 4 24 (11.2%) 7.00 (7.00) 128.56
Sample size
Group 1 127 (56.2%) 94.00 (75.00) 105.92 0.002
Group 2 48 (21.2%) 99.50 (115.50) 115.90
Group 3 27 (11.9%) 63.00 (176.00) 103.22
Group 4 24 (10.6%) 221.00 (235.00) 160.40
Duration of disease
Group 1 46 (47.9%) 12.00 (97.50) 53.15 0.278
Group 2 24 (25.0%) 12.00 (45.00) 43.81
Group 3 17 (65.4%) 12.00 (64.80) 46.74
Group 4 9 (9.4%) 12.00 (30.00) 40.56
Interventions
Course of treatment
Group 1 126 (56.3%) 8.00 (6.00) 111.19 0.070
Group 2 47 (21.0%) 8.00 (2.00) 99.91
Group 3 27 (12.1%) 8.00 (0.00) 116.04
Group 4 24 (10.7%) 8.00 (18.00) 140.06
Outcomes
Adverse events rate
Group 1 120 (51.9%) 0.13 (0.12) 114.79 0.047
Group 2 53 (22.9%) 0.15 (0.16) 132.80
Group 3 33 (14.3%) 0.11 (0.12) 115.09
Group 4 25 (10.8%) 0.10 (0.11) 87.40
IQR, inter-quartile range.
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Multiple linear regressions were further used to explore
possible dominants relate to internal validity (The grading score of
internal validity taken as dependent variable), we found sample
size, industry-funding, the reporting of quality of life and university
afﬁliated hospital as the trial setting, were associated with internal
validity (P < 0.001, P < 0.001, P ¼ 0.001, P ¼ 0.006 respectively), of
those, the sample size rank as the ﬁrst choice (0.253) based on the
standardized beta coefﬁcients (Table 5).
4. Discussion
More and more methodologists and practitioners of researches
consider that internal validity and external validity stand in aTable 5
Multiple linear regression for essential aspects of external validity to internal validity.
Unstandardized
coefﬁcients
Standardiz
b SE
Constant 2.698 0.176 e
Sample size 0.308 0.075 0.253
Industry-funding 0.577 0.154 0.229
Quality of life 1.084 0.329 0.200
University afﬁliated hospital 0.455 0.164 0.172
t, t-value; CI, conﬁdence interval; SE, standard error.relationship best described as a “trade-off” [19e21] (the more we
ensure that the treatment is isolated from potential confounders in
order to make certain that the observed effect is attributable to the
treatment, the more unlikely it is that the experimental results can
be representative of phenomena of the outside world). Although
this seems to be the standard view regarding the relationship be-
tween internal and external validity, it is not the only one. Another
idea that internal validity is in a prerequisite to external validity
was also found [22e25]. Although these two positions need not
necessarily be contradictory, they do not stand in an easy associa-
tion to each other. The existence of a relationship between internal
and external validity constitutes a commonplace in the experi-
mental and in the methodological literature around experimental
medicine. In this study, we attempt to use a sample of hypertension
RCTs conducted in China to explore the relationship between the
external and internal validity systematically.
There are several interesting ﬁndings in our study. Firstly, in-
ternal validity associated with trials setting, either university afﬁl-
iated hospital or secondary/tertiary hospital, seem to have higher
grading score of internal validity. That can be explained by the
research capacity of personnel and institutes; trials conducted at
above hospitals may suffer from less systematic error [14]. On the
contrast, for clinicians in primary hospitals, high workloads and
poor knowledge and research skills have been identiﬁed as main
barriers to undertaking good research [26,27]. Secondly, industry-
funded RCTs were graded higher score of internal validity too.
This ﬁnding is consistent with that of a demonstrating that the
trials supported by industry had better methodological quality [15].
Industry-funded trials having more ﬁnancial resources were more
likely to be designed as large scale, multicenter, international trials,
the more likely it is that the trials results can be representative of
phenomena of real world; besides, industry funding trials were
more likely to be published in journals with a higher impact factor
[16] and accordingly, were more likely to be of adequate method-
ological quality [15,17]. Domains relate to internal validity were
further investigated in our study, but the associations between
funding and each domains of internal validity were not found.
Another study conducted by Mugambi et al. [18] identiﬁed there
was no signiﬁcant association between funding source and meth-
odological quality of RCTs in terms of sequence generation, allo-
cation concealment, blinding and selective reporting. However,
there was a signiﬁcant association between funding and method-
ological quality of RCTs in the domains of incomplete outcome data
and free of other bias. Industry funded trials had a higher per-
centage of free of other bias as well as had less missing data than
those of non-industry funded trials signiﬁcantly.
Thirdly, similar to another report [17], our study revealed a
signiﬁcant association between the number of research centers and
the internal validity of these trials. The beneﬁts of multicenter trials
include a larger number of participants (they differ along a wide
range of factors, such in age, gender, behavior, height, intelligence,
and so forth.) recruited, different geographic locations, theed coefﬁcients (b) t P value 95%CI for b
15.338 <0.001 2.351e3.044
4.135 <0.001 0.161e0.455
3.751 <0.001 0.274e0.880
3.294 0.001 0.435e1.732
2.770 0.006 0.131e0.778
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the ability to compare results among centers, all of which increase
the generalizability of those multicenter trials and meanwhile are
more likely to reduce the risk of biases, increase statistical power
and precision. As both internal and external validity beneﬁt from
multicenter trials, such kinds of trial seem to be a preferred choice
in clinical researches.
Fourthly, internal validity beneﬁts from the trial setting selected
as well as the reporting of stringent eligibility criteria. However, in
this situation, the internal validity and external validity stand in a
“trade-off” relationship. The inclusion and exclusion criteria for a
RCT are designed to identify a population of interest in whom an
intervention has the greatest likelihood to produce a clinically
important and statistically signiﬁcant effect [28]. The advantages of
stringent eligibility criteria are achieved at the risk of excluding
patients who may be more likely to represent the population
treated in clinical settings and who would better test an in-
tervention's effectiveness.
Fifthly, the RCTs with a larger sample size were more likely to be
graded a higher score of internal validity. Trial large enough will
have a high probability (power) of detecting as statistically signif-
icant a clinically important difference of a given size if such a dif-
ference exists [29], on contrast, reports of RCTs with small samples
frequently include the erroneous conclusion that the intervention
groups do not differ, when in fact too few patients were studied to
make such a claim [30]. In addition, insufﬁcient trial size may cause
over homogenous patients to be enrolled (selection biases);
simultaneously, since one of the main goals of dissertations that
adopt RCT research design is to make generalizations from the
sample being studied to the population the sample is drawn from,
and in some cases, across populations, selection biases are arguably
one of the most signiﬁcant threats to external validity.
Sixthly, trials adopting quality of life as the patient preferred
outcome have higher internal validity too. Quality of life (QoL) is the
subjective perception of how an individual feels about their health
status and/or the non-medical aspects of their lives [31,32]. As the
need for a more holistic view of outcome during and following
illness is required, the role of QoLmeasurement assumes increasing
importance [33] and is particularly important for patients with
chronic diseases (e.g., hypertension) [34e37]. Required as an end
point of clinical trials [33], a measure of QoL instead of surrogate
parameters (e.g. laboratory values) may improve the representa-
tiveness of a study population (improving external validity syn-
chronously) [35]. However, the explanation by which the RCTs
reporting QoL as an outcome may exert better internal validity has
not been known.
There are several limitations in our study. Of those, the poor
reporting in most included RCTs make it hard to analyze the rela-
tionship between the external and internal validity thoroughly
[38]; information related to external validity was not reported or
was reported insufﬁciently too, there is marked room for improving
quality of the reporting in RCTs, especially at the respects related to
external validity. In addition, because the methodological quality of
an RCT was assessed based on its published report, we cannot be
certain whether our ﬁndings represent incomplete reporting or
inadequate performance of these measures. Plausibly, investigators
may not have reported important quality measures despite their
adequate performance, causing an underestimation of the study
internal validity.
Finally, including studies conﬁned in China and in a certain ﬁeld
may impact the external validity of our research. Future research
may concentrate on the other therapeutic areas or other counties
using the approach reported in this research to explore the rela-
tionship between the external and internal validity of RCTs; the
results of these two research studies could then be compared.5. Conclusion
This study has identiﬁed the relationship between the internal
validity and several domains of the external validity of RCTs in
China, that do not stand in an easy relationship to each other.
Taking factors that can inﬂuence the representativeness of a study
population to makeup of external validity to explore the relation-
ship between the internal and external validity is somewhat
feasible; other possible links between two validities needed to
demonstrate in the future methodological researches.
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